focus -WSS

focus

author：leisure time 2025-10-02 01:07:49 - browse：3

Pfizer and Moderna aren’t the only vaccine money-makers. Much of the revenue and profits from Covid-19 vaccines are flowing behind the scenes, going to the contract manufacturers and clinical-trial organizers that turn the shots from lab-bench theory to mass-produced reality.

Both AstraZeneca and Johnson & Johnson publicly committed to not profiting off their products during the pandemic — though AstraZeneca has reserved the right to declare the pandemic over on July 1, even if the World Health Organization has not. Pfizer and Moderna made no such pledge, with Pfizer expected to make $15 billion in vaccine-related revenue this year, while Moderna is forecasting $18.4 billion in vaccine sales.

Contractors hired to test and manufacture these vaccines have enjoyed a share of the profits without the same level of public scrutiny.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Hollywood unions extend contract negotiations for actors
Next article： FDA early review: GLP

WSS

STAT Virtual Event: JPM Recap, Live!

Hospitals, health systems can help patients avoid medical debt

Interest rates are at a 22

VC firm RA Capital starts a new synthetic biology incubator

Life science postdocs should get big pay hike, NIH panel says

Medicare Advantage coverage denials need scrutiny, senators say

focus

focus

focus

Novavax promises a turnaround & Lilly roils the obesity market

Interest rates are at a 22

Tori Bowie and the unacceptable rates of Black maternal death

Gene therapy denied for Afghan refugee whose father aided U.S.

Malaria cases in Florida and Texas: Here’s what you need to know

Stoke drug shows lower activity against childhood epilepsy

Apple is now the first public company to be valued at $3 trillion

Medicare Advantage overpayments discussion gets experts fired up

Virginia high school admissions case could be legal follow

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

focus

Behind warning on Apellis’s eye drug lies a conflict of interest

Behind warning on Apellis’s eye drug lies a conflict of interest

VC firm RA Capital starts a new synthetic biology incubator

In shift, Texas to cover initial consult for Afghan baby's gene therapy

Stories you might have missed in 2023: health, science, medicine

Nonprofit, backed by Microsoft, to certify AI tools in health care

hotspot

Wikipedia

hotspot

focus